C9069 Belantamab mafodotin-blmf - CanMED: HCPCS

Return Home

Home

SEER Data & Software

Observational Research in Oncology Toolbox

Medication Information

CanMED: HCPCS

Generic Name:

Belantamab mafodotin-blmf

Brand Name:

Blenrep

Strength:

0.5mg

HCPCS:

C9069

SEER*Rx Category:

Immunotherapy

Major Drug Class:

Drug Antibody Conjugate

Minor Drug Class:

BCMA

Oral (Y/N):

No

FDA Approval Year:

2020

FDA Discontinuation Year:

CMS Effective Date:

Jan. 1, 2021

CMS Discontinuation Date:

Status:

No Longer Used